AUS
NZ
UK
CA
USA
IND
_06_19_2026_12_34_15_139937.jpg)
Highlights
- Stake adjustments by major financial entities reflect structured participation.
- Stock performance variations align with analyst evaluations.
- Advanced software solutions support drug discovery and development.
Simulations Plus Inc. is part of NASDAQ Healthcare Stocks, specializing in advanced software solutions for drug discovery and development. The company leverages artificial intelligence and machine learning to enhance pharmaceutical modeling and simulation. With institutional stake adjustments and ongoing software advancements, Simulations Plus remains engaged in delivering cutting-edge tools for the healthcare and pharmaceutical industries.
Institutional Transactions and Stake Adjustments
Simulations Plus (NASDAQ:SLP) has experienced modifications in financial participation, with several firms adjusting positions. SG Americas Securities LLC reduced its stake by 3.7% in the fourth quarter, selling 958 shares and adjusting its holdings to 25,011 shares.
Additional financial entities, including JPMorgan Chase & Co., Principal Financial Group Inc., and Franklin Resources Inc., expanded their positions. JPMorgan increased its stake by 106%, now holding 47,365 shares, while Principal Financial Group Inc. owns 87,273 shares after increasing its holdings. Franklin Resources Inc. raised its stake by 7.6%, reinforcing structured financial engagement.
Barclays PLC significantly expanded its position by 390.6%, reflecting increased participation. Geode Capital Management LLC also adjusted its stake, holding 448,618 shares after a 4.4% increase. These transactions contribute to structured engagement, with institutions collectively holding approximately 78.08% of Simulations Plus' stock.
Stock Performance and Analyst Evaluations
Simulations Plus' stock recently opened at $34.27, reflecting structured financial assessments. The company's valuation has fluctuated within a 12-month range between $24.00 and $51.22.
Financial analysts have provided varied assessments, with BTIG Research adjusting its target price from $60.00 to $50.00. Other assessments include Stephens and KeyCorp issuing revised target prices of $39.00 and $37.00, respectively. These evaluations contribute to structured financial insights on the company's engagement in drug discovery solutions.
Software Solutions and Technological Advancements
Simulations Plus specializes in drug discovery and development software, utilizing artificial intelligence and machine learning. The company's technology supports modeling, simulation, and molecular property prediction.
Key products include GastroPlus, DDDPlus, and MembranePlus, which facilitate predictive analytics in human and animal compound interactions. The company's structured development of software solutions supports pharmaceutical advancements.
Industry Presence and Long-Term Engagement
With institutional participation and software advancements shaping operations, Simulations Plus remains engaged in structured technology development. The company’s focus on predictive modeling solutions strengthens its role in pharmaceutical research and development.
Simulations Plus continues to expand software capabilities while maintaining structured financial strategies. Its engagement in drug discovery analytics supports ongoing developments in pharmaceutical technology.
